Evolving chemotherapeutics

Independent Data Safety Monitor Recom...

FivepHusion today announces important progress in its ongoing FP101A phase 1b/2a dose-escalation clinical study of Deflexifol™ in patients with advanced solid tumours: Deflexifol™ is an optimised all-in-one formulation of the chemotherapeutic agents 5-fluorouracil (5-FU) and leucovorin (LV) for the treatment of solid tumours The ongoing FP101A phase 1b/2a clinical study is designed to confirm the […]

Independent Expert Clinical Advisory ...

FivepHusion today announces the establishment of an independent, expert Clinical Advisory Board (CAB) comprising some of Australia’s leading clinical experts in oncology and pharmacology. The board will advise and guide our company on the ongoing development of Deflexifol™, an optimised formulation of the chemotherapeutic agents 5-fluoruracil (5-FU) and leucovorin (LV) for the treatment of solid […]

Bridging Trial Recruiting at Dose Lev...

The bridging PK study of Deflexifol is progressing well. Study chief investigator Associate Professor Daniel Brungs reports that patients are now expected to be recruited to Dose Level 4, subject to approval by the Independent Data Safety Monitor. 14 patients have been treated so far, including 4 at Dose Level 3 without any SAEs. The […]

BIO 2021

FivepHusion will be attending and presenting at BIO Digital 2021, on June 14-18. As it prepares for its phase III pivotal registration trial, FivepHusion is seeking investment and strategic partners to pursue registration and commercialisation of Deflexifol™ as the new standard of care for solid tumor treatment.

Bridging trial underway

The bridging PK study of Deflexifol is reported to be progressing well. Sponsored by Detsamma Investments under an out-license from FivepHusion, the clinical trial is being undertaken at the Southern Medical Day Care Centre in Wollongong, Australia. Study chief investigator Associate Professor Daniel Brungs reports that patients are still being recruited to Dose Level 2, […]

Detsamma and FivepHusion to begin bri...

Detsamma Investments and its partner FivepHusion have received human ethics approval to begin its bridging PK study of Deflexifol. This study will gather improved PK data and further efficacy signals in a regimen that matches SOC for 5-FU and Leucovorin.

New partnership to fund Deflexifol br...

Fivephusion has concluded a drug development partnership deal with Detsamma Investments Pty Ltd. Detsamma will fund the further development of Deflexifol, including completing a bridging trial to gather extra data sought by the FDA. Detsamma Investments plans to complete the bridging trial in 2020, and follow this with a pre-IND meeting with the FDA. Detsamma […]

David Ranson presents at Ausbiotech I...

David Ranson presents at Ausbiotech Invest conference

David Ranson presented the Deflexifol opportunity at the recent Ausbiotech Invest and Partnering 2018 conference in Melbourne, Australia (http://ausbiotechinvestment.com.au/australia-biotech-invest/event-details)

ASCO 2017 – Detailed clinical t...

ASCO 2017 – Detailed clinical trial results presented

The phase 1 trial results were presented in greater detail in two posters at ASCO 2017 in Chicago this week. Professor Phil Clingan presented a poster: Deflexifol (a novel formulation of 5FU) Phase 1 Dose Escalation Study of Infusional or Bolus Schedules After Failure of Standard Treatment Clingan P. et al J Clin Oncol 35, 2017 […]

Trial results presented at ASCO GI, 2...

Trial results presented at ASCO GI, 2017

A poster presentation by Professor Phil Clingan summarizing phase 1 results has been presented at the ASCO GI conference, San Francisco, January 19-21, 2017. J Clin Oncol 35, 2017 (suppl 4S; abstract TPS812)  

Deflexifol is safer for patients

Deflexifol is safer for patients

Preclinical evaluation of novel, all-in-one formulations of 5-fluorouracil and folinic acid with reduced toxicity profiles. Click to read this article.

Potent, with fewer side effects

Potent, with fewer side effects

Deflexifol (formerly Fluorodex) maintains in-vitro potency, overcomes incompatibility of 5-fluorouracil and folinic acid and may reduce phlebitis, catheter blockages and thromboembolic events. Development and assessment of novel all-in-one parenteral formulations with integrated anticoagulant properties for the concomitant delivery of 5-fluorouracil and calcium folinate. Read our article signalling improved patient outcomes from Deflexifol.

New hope for patients

New hope for patients

New hope being offered by Deflexifol to chemotherapy patients. Read here about new hope for chemotherapy patients.

New way to use an older drug

New way to use an older drug

Deflexifol is a new way of using an older drug. Read more.

Bio-Link to assist FivepHusion with B...

Bio-Link to assist FivepHusion with Business Development

FivepHusion have engaged Bio-Link Australia to assist with business development and out-licensing opportunities for Deflexifol. Bio-Link (http://bio-link.com/) is a strategic consulting and biotechnology business development company that works with Australian and international life sciences companies and academic institutions to facilitate deals based on strategic technology analysis and consulting, business development, project management and deal negotiation.